Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 9.23% is 92% below its 5-year average of 115.79%, near the low end of its 5-year range (4.58%–476.46%).
As of the fiscal period ended Tuesday, June 30, 2026. 22.84% above its 12-month average of 7.52%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 9.23%.
DEBT TO ASSETS RATIO
9.23%
DEBT TO ASSETS RATIO AVG TTM
7.52%
DEBT TO ASSETS RATIO AVG 3Y
6.75%
DEBT TO ASSETS RATIO AVG 5Y
115.79%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+22.84%
CURRENT VS 3Y AVG
+36.90%
CURRENT VS 5Y AVG
-92.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+9134.88%
vs the sector median at left
Genelux Corporation
Market Cap
$114.57M
Debt to Assets Ratio
9.23%
TTM Avg
7.52%
3Y Avg
6.75%
5Y Avg
115.79%
Market Cap
$116.54M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.57M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.83M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.52M
Debt to Assets Ratio
0.64%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.36M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.73M
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.91M
Debt to Assets Ratio
0.65%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genelux Corporation (GNLX) | $114.57M | 9.23% | 7.52% | 6.75% | 115.79% |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | 0.09% | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | 0.19% | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | 0.09% | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.83M | 0.00% | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $112.52M | 0.64% | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $112.36M | 0.00% | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $110.73M | 0.07% | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.91M | 0.65% | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.24M | 0.01% | N/A | N/A | N/A |
Debt/Assets
9.2%
Debt/Equity
0.15
Current Ratio
2.39
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 9.23% |
| 2026-03-31 | 7.71% |
| 2025-12-31 | 8.86% |
| 2025-09-30 | 6.50% |
| 2025-06-30 | 5.29% |
| 2025-03-31 | 4.58% |
| 2024-12-31 | 5.38% |
| 2024-09-30 | 5.06% |
| 2024-06-30 | 4.89% |
| 2024-03-31 | 9.61% |
| 2023-12-31 | 9.03% |
| 2023-09-30 | 5.56% |
| 2023-06-30 | 5.99% |
| 2023-03-31 | 24.73% |
| 2022-12-31 | 476.46% |
| 2022-09-30 | 410.70% |
| 2022-06-30 | 278.92% |
| 2022-03-31 | 246.47% |
| 2021-12-31 | 311.48% |
| 2021-09-30 | 297.54% |
| 2021-06-30 | 297.54% |
| 2021-03-31 | 244.73% |
| 2020-12-31 | 186.04% |
| 2020-09-30 | 180.60% |
| 2020-06-30 | 180.60% |
